神经病变治疗药的全球市场:现状分析·预测(2022年～2028年)

全球神经病变治疗药的市场规模在预测期间内预计将以约5％显着的成长率推移。

由于熟练的医生的存在以及治疗的安全性和有效性，预计该市场将显示出最快的增长速度。越来越多的神经血管疾病患者（如脑动脉瘤、动静脉畸形等）也促进了市场增长。

本报告提供全球神经病变治疗药市场相关调查，提供收益，疾病·药物类别·流通管道·各地区的市场洞察，市场动态，机会，趋势，企业简介等相关资讯。

目录

第1章 市场简介

• 市场定义
• 主要目的
• 相关利益者
• 限制

第2章 调查手法或前提条件

• 神经病变治疗药市场调查流程
• 神经病变治疗药市场调查手法
• 受访者简介

第3章 市场摘要

第4章 摘要整理

第5章 神经病变治疗药市场上COVID-19影响

第6章 神经病变治疗药市场收益(10亿美元)，2020年～2028年F

第7章 市场洞察:各疾病

• 神经血管疾病
• 中枢神经系统外伤
• 神经退化性疾病
• 感染疾病
• 中枢神经系统癌症
• 其他

第8章 市场洞察:各药物类别

• 止痛药
• 麻醉剂
• 抗痉挛药
• 抗癫痫药
• 抗帕金森氏症药
• 其他

第9章 市场洞察:各流通管道

• 医院药局
• 零售药局
• 线上药局
• 其他

第10章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他的北美
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他的欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他的亚太地区
• 其他地区

第11章 神经病变治疗药:市场动态

• 推动市场要素
• 市场课题
• 影响分析

第12章 神经病变治疗药市场:机会

第13章 神经病变治疗药市场:趋势

第14章 需求面·供给面分析

• 需求面分析
• 供给面分析

第15章 价值链分析

第16章 竞争模式

• 竞争情形
  • 波特的五力分析

第17章 企业简介

• AbbVie Inc.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Johnson and Johnson
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Merck KGaA

第18章 免责声明

The global neurologic disorders therapeutics Market is expected to grow at a significant rate of around 5% during the forecast period. Neurologic disorder is a disorder of the nervous system. As per various studies, the growth of these neurological disorders is spreading rapidly across the world and becoming increasingly common, especially neurodegenerative diseases. Furthermore, Neurologic disorders therapeutics is expected to have the fastest growth rate in the market mainly due to the availability of skilled healthcare professionals, and the safety & efficacy during the treatment procedures. Moreover, the growing patient pool suffering from neurovascular diseases such as brain aneurysms, and arteriovenous malformations are also contributing to the growth of this market during the forecast period. For instance, according to the Brain Aneurysms Foundation, about 30,000 people in the United States suffer a brain aneurysm rupture each year.

AbbVie Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Merck KGaA are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst disease type, neurodegenerative diseases category to witness robust CAGR during the forecast period"

Based on disease type, the market is segmented into neurovascular diseases, CNS trauma, neurodegenerative diseases, infectious diseases, CNS cancer, and others. The neurodegenerative diseases category is to witness considerable growth during the forecast period. This is mainly due to the increasing brain injuries, cerebral disorders, and rising prevalence of hypertension in the geriatric population are the major factors for the growth of the neurologic disorder's therapeutics market during the forecast period. For instance, according to the Brain Aneurysm Foundation, an estimated 6 million Americans are affected by cerebral aneurysms.

"Amongst drug class, the antiepileptics to hold a significant share in the market in 2020"

On the basis of drug class, the market is categorized into analgesics, anesthetics, anticonvulsants, antiepileptics, antiparkinson agents, and others. Among these, the antiepileptics category is to witness significant growth during the forecast period. This is mainly due to these drugs prevent seizures, either by decreasing excitation or enhancing inhibition. Moreover, the growing prevalence of epilepsy demanding for therapeutically effective medications is creating pressure among the market players to introduce AEDs. For instance, in January 2020, Eisai Co. Ltd. announced the launch of FYCOMPA in China for the treatment of partial-onset seizures in patients aged 12 years and older.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the neurologic disorders therapeutics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is expected to witness significant growth in the market owing to the availability of market players in the region and the rising initiative undertaken by key players to develop various therapies for different neurological disorders are the major factors that are expected to increase the market share. Moreover, the growing cases of mental health and neurodegenerative disorders such as multiple sclerosis, Alzheimer's, Parkinson's disease, and brain cancer is fueling the demand for neurologic disorders therapeutics in the region. For instance, around 70,800 people in the United States are diagnosed with brain cancer every year, which represents 1.4% of the total cancer incidence and causes about 2.4% of all cancer deaths in the U.S.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at one glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional level analysis of the industry.

Customization Options:

The global neurologic disorders therapeutics market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Neurologic Disorders Therapeutics Market
• 2.2. Research Methodology of the Neurologic Disorders Therapeutics Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE NEUROLOGIC DISORDERS THERAPEUTICS MARKET

6 NEUROLOGIC DISORDERS THERAPEUTICS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DISEASES

• 7.1. Neurovascular Diseases
• 7.2. CNS Trauma
• 7.3. Neurodegenerative Diseases
• 7.4. Infectious Diseases
• 7.5. CNS Cancer
• 7.6. Others

8 MARKET INSIGHTS BY DRUG CLASS

• 8.1. Analgesics
• 8.2. Anesthetics
• 8.3. Anticonvulsants
• 8.4. Antiepileptics
• 8.5. Anti-Parkinson Agents
• 8.6. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 NEUROLOGIC DISORDERS THERAPEUTICS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 NEUROLOGIC DISORDERS THERAPEUTICS MARKET OPPORTUNITIES

13 NEUROLOGIC DISORDERS THERAPEUTICS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Five Forces Analysis

17 COMPANY PROFILED

• 17.1. AbbVie Inc.
• 17.2. F. Hoffmann La Roche Ltd.
• 17.3. GlaxoSmithKline Plc
• 17.4. Johnson and Johnson
• 17.5. Mylan NV
• 17.6. Novartis AG
• 17.7. Pfizer Inc.
• 17.8. Sanofi
• 17.9. Teva Pharmaceutical Industries Ltd.
• 17.10. Merck KGaA

18 DISCLAIMER